The Lysophosphatidic Acid Type 2 Receptor Is Required for Protection Against Radiation-Induced Intestinal Injury

Gastroenterology

Volumn 132, Issue 5, 2007, Pages 1834-1851

  Deng, Wenlin ^a,b   E, Shuyu ^a   Tsukahara, Ryoko ^a   Valentine, William J ^a   Durgam, Gangadhar ^a   Gududuru, Veeresa ^a,b   Balazs, Louisa ^a   Manickam, Venkatraman ^a   Arsura, Marcello ^a   Vanmiddlesworth, Lester ^a   Johnson, Leonard R ^a   Parrill, Abby L ^c   Miller, Duane D ^a   Tigyi, Gabor ^a,c  

^a UNIVERSITY OF TENNESSEE HEALTH SCIENCE CENTER   (United States)

^b RxBio Inc   (United States)

^c University of Memphis   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CAMPTOTHECIN; CASPASE 3; CASPASE 8; CASPASE 9; CYCLOHEXIMIDE; LYSOPHOSPHATIDIC ACID; LYSOPHOSPHATIDIC ACID RECEPTOR; LYSOPHOSPHATIDIC ACID TYPE 1 RECEPTOR; LYSOPHOSPHATIDIC ACID TYPE 2 RECEPTOR; LYSOPHOSPHATIDIC ACID TYPE 3 RECEPTOR; OCTADECENYL THIOPHOSPHATE; PHOSPHOROTHIOIC ACID DERIVATIVE; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CELL LINE; CELL SURVIVAL; CONTROLLED STUDY; CRYPT CELL; ENZYME ACTIVITY; FEMALE; GAMMA IRRADIATION; INTESTINE CRYPT; INTESTINE EPITHELIUM CELL; INTESTINE INJURY; KNOCKOUT MOUSE; LETHAL DOSE; MOUSE; NONHUMAN; PRIORITY JOURNAL; RADIATION DOSE; RADIATION INJURY; RAT; WILD TYPE;

EID: 34247850836     PISSN: 00165085     EISSN: None     Source Type: Journal    
DOI: 10.1053/j.gastro.2007.03.038     Document Type: Article

References (61)

1. Potten C.S. Radiation, the ideal cytotoxic agent for studying the cell biology of tissues such as the small intestine. Radiat Res 161 (2004) 123-136
2. Tigyi G., and Parrill A.L. Molecular mechanisms of lysophosphatidic acid action. Prog Lipid Res 42 (2003) 498-526
3. Moolenaar W.H., van Meeteren L.A., and Giepmans B.N. The ins and outs of lysophosphatidic acid signaling. Bioessays 26 (2004) 870-881
4. Ishii I., Fukushima N., Ye X., and Chun J. Lysophospholipid receptors: signaling and biology. Annu Rev Biochem 73 (2004) 321-354
5. Noguchi K., Ishii S., and Shimizu T. Identification of p2y9/GPR23 as a novel G protein-coupled receptor for lysophosphatidic acid, structurally distant from the Edg family. J Biol Chem 278 (2003) 25600-25606
6. Kotarsky K., Boketoft A., Bristulf J., Nilsson N.E., Norberg A., Hansson S., Owman C., Sillard R., Leeb-Lundberg L.M., and Olde B. Lysophosphatidic acid binds to and activates GPR92, a G protein-coupled receptor highly expressed in gastrointestinal lymphocytes. J Pharmacol Exp Ther 318 (2006) 619-628
7. Lee C.W., Rivera R., Gardell S., Dubin A.E., and Chun J. GPR92 as a new G12/13- and Gq-coupled lysophosphatidic acid receptor that increases cAMP, LPA5. J Biol Chem 281 (2006) 23589-23597
8. Li C., Dandridge K.S., Di A., Marrs K.L., Harris E.L., Roy K., Jackson J.S., Makarova N.V., Fujiwara Y., Farrar P.L., Nelson D.J., Tigyi G.J., and Naren A.P. Lysophosphatidic acid inhibits cholera toxin-induced secretory diarrhea through CFTR-dependent protein interactions. J Exp Med 202 (2005) 975-986
9. Yun C.C., Sun H., Wang D., Rusovici R., Castleberry A., Hall R.A., and Shim H. LPA2 receptor mediates mitogenic signals in human colon cancer cells. Am J Physiol Cell Physiol 289 (2005) C2-C11
10. A3/EDG-7 in neuronal cell lines using a retrovirus expression system. Mol Pharmacol 58 (2000) 895-902
11. Yart A., Chap H., and Raynal P. Phosphoinositide 3-kinases in lysophosphatidic acid signaling: regulation and cross-talk with the Ras/mitogen-activated protein kinase pathway. Biochim Biophys Acta 1582 (2002) 107-111
12. Deng W., Balazs L., Wang D.A., Van Middlesworth L., Tigyi G., and Johnson L.R. Lysophosphatidic acid protects and rescues intestinal epithelial cells from radiation- and chemotherapy-induced apoptosis. Gastroenterology 123 (2002) 206-216
13. Deng W., Wang D.A., Gosmanova E., Johnson L.R., and Tigyi G. LPA protects intestinal epithelial cells from apoptosis by inhibiting the mitochondrial pathway. Am J Physiol Gastrointest Liver Physiol 284 (2003) G821-G829
14. Ye X., Ishii I., Kingsbury M.A., and Chun J. Lysophosphatidic acid as a novel cell survival/apoptotic factor. Biochim Biophys Acta 1585 (2002) 108-113
15. Kang Y.C., Kim K.M., Lee K.S., Namkoong S., Lee S.J., Han J.A., Jeoung D., Ha K.S., Kwon Y.G., and Kim Y.M. Serum bioactive lysophospholipids prevent TRAIL-induced apoptosis via PI3K/Akt-dependent cFLIP expression and Bad phosphorylation. Cell Death Differ 11 (2004) 1287-1298
16. Fang X., Yu S., Eder A., Mao M., Bast Jr. R.C., Boyd D., and Mills G.B. Regulation of BAD phosphorylation at serine 112 by the Ras-mitogen-activated protein kinase pathway. Oncogene 18 (1999) 6635-6640
17. Chou C.H., Wei L.H., Kuo M.L., Huang Y.J., Lai K.P., Chen C.A., and Hsieh C.Y. Up-regulation of interleukin-6 in human ovarian cancer cell via a Gi/PI3K-Akt/NF-kappaB pathway by lysophosphatidic acid, an ovarian cancer-activating factor. Carcinogenesis 26 (2005) 45-52
18. Fischer D.J., Liliom K., Guo Z., Nusser N., Virag T., Murakami-Murofushi K., Kobayashi S., Erickson J.R., Sun G., Miller D.D., and Tigyi G. Naturally occurring analogs of lysophosphatidic acid elicit different cellular responses through selective activation of multiple receptor subtypes. Mol Pharmacol 54 (1998) 979-988
19. A1 lysophosphatidic acid receptor gene in normal suckling behavior. Proc Natl Acad Sci U S A 97 (2000) 13384-13389
20. Contos J.J., Ishii I., Fukushima N., Kingsbury M.A., Ye X., Kawamura S., Brown J.H., and Chun J. Characterization of lpa(2) (Edg4) and lpa(1)/lpa(2) (Edg2/Edg4) lysophosphatidic acid receptor knockout mice: signaling deficits without obvious phenotypic abnormality attributable to lpa(2). Mol Cell Biol 22 (2000) 6921-6929
21. Ye X., Hama K., Contos J.J., Anliker B., Inoue A., Skinner M.K., Suzuki H., Amano T., Kennedy G., Arai H., Aoki J., and Chun J. LPA3-mediated lysophosphatidic acid signalling in embryo implantation and spacing. Nature 435 (2005) 104-108
22. Chevreau N., and Funk-Archuleta M. Effect of enteral formulas on methotrexate toxicity. Nutr Cancer 23 (1995) 185-204
23. Funk-Archuleta M.A., Foehr M.W., Tomei L.D., Hennebold K.L., and Bathurst I.C. A soy-derived antiapoptotic fraction decreases methotrexate toxicity in the gastrointestinal tract of the rat. Nutr Cancer 29 (1997) 217-221
24. Logvinova A.V., Foehr M.W., Pemberton P.A., Khazalpour K.M., Funk-Archuleta M.A., Bathurst I.C., and Tomei L.D. Soy-derived antiapoptotic fractions protect gastrointestinal epithelium from damage caused by methotrexate treatment in the rat. Nutr Cancer 33 (1999) 33-39
25. Tokumura A., Fukuzawa K., Akamatsu Y., Yamada S., Suzuki T., and Tsukatani H. Identification of vasopressor phospholipid in crude soybean lecithin. Lipids 13 (1978) 468-472
26. Sturm A., and Dignass A.U. Modulation of gastrointestinal wound repair and inflammation by phospholipids. Biochim Biophys Acta 1582 (2002) 282-288
27. Sano T., Baker D., Virag T., Wada A., Yatomi Y., Kobayashi T., Igarashi Y., and Tigyi G. Multiple mechanisms linked to platelet activation result in lysophosphatidic acid and sphingosine 1-phosphate generation in blood. J Biol Chem 277 (2002) 21197-21206
28. Hines O.J., Ryder N., Chu J., and McFadden D. Lysophosphatidic acid stimulates intestinal restitution via cytoskeletal activation and remodeling. J Surg Res 92 (2000) 23-28
29. Hall P.A., Coates P.J., Ansari B., and Hopwood D. Regulation of cell number in the mammalian gastrointestinal tract: the importance of apoptosis. J Cell Sci 107 (1994) 3569-3577
30. Pritchard D.M., and Watson A.J. Apoptosis and gastrointestinal pharmacology. Pharmacol Ther 72 (1996) 149-169
31. Deng W., Poppleton H., Yasuda S., Makarova N., Shinozuka Y., Wang D.A., Johnson L.R., Patel T.B., and Tigyi G. Optimal lysophosphatidic acid-induced DNA synthesis and cell migration but not survival require intact autophosphorylation sites of the epidermal growth factor receptor. J Biol Chem 279 (2004) 47871-47880
32. Parrill A.L., Wang D., Bautista D.L., Van Brocklyn J.R., Lorincz Z., Fischer D.J., Baker D.L., Liliom K., Spiegel S., and Tigyi G. Identification of Edg1 receptor residues that recognize sphingosine 1-phosphate. J Biol Chem 275 (2000) 39379-39384
33. 1 (EDG2) phospholipid growth factor receptors. J Biol Chem 276 (2001) 49213-49220
34. Sardar V.M., Bautista D.L., Fischer D.J., Yokoyama K., Nusser N., Virag T., Wang D.A., Baker D.L., Tigyi G., and Parrill A.L. Molecular basis for lysophosphatidic acid receptor antagonist selectivity. Biochim Biophys Acta 1582 (2002) 309-317
35. Parrill A.L., Sardar V.M., and Yuan H. Sphingosine 1-phosphate and lysophosphatidic acid receptors: agonist and antagonist binding and progress toward development of receptor-specific ligands. Semin Cell Dev Biol 15 (2004) 467-476
36. Fujiwara Y., Sardar V., Tokumura A., Baker D.L., Murakami-Murofushi K., Parrill A.L., and Tigyi G. Identification of residues responsible for ligand recognition and regioisomeric selectivity of LPA receptors expressed in mammalian cells. J Biol Chem 280 (2005) 35038-35050
37. Inagaki Y., Pham T.T., Fujiwara Y., Kohno T., Osborne D.A., Igarashi Y., Tigyi G., and Parrill A.L. Sphingosine 1-phosphate analogue recognition and selectivity at S1P4 within the endothelial differentiation gene family of receptors. Biochem J 389 (2005) 187-195
38. Jo E., Sanna M.G., Gonzalez-Cabrera P.J., Thangada S., Tigyi G., Osborne D.A., Hla T., Parrill A.L., and Rosen H. S1P1-selective in vivo-active agonists from high-throughput screening: off-the-shelf chemical probes of receptor interactions, signaling, and fate. Chem Biol 12 (2005) 703-715
39. Virag T., Elrod D.B., Liliom K., Sardar V.M., Parrill A.L., Yokoyama K., Durgam G., Deng W., Miller D.D., and Tigyi G. Fatty alcohol phosphates are subtype-selective agonists and antagonists of LPA receptors. Mol Pharmacol 63 (2003) 1032-1042
40. Durgam G.G., Virag T., Walker M.D., Tsukahara R., Yasuda S., Liliom K., van Meeteren L.A., Moolenaar W.H., Wilke N., Siess W., Tigyi G., and Miller D.D. Synthesis, structure-activity relationships, and biological evaluation of fatty alcohol phosphates as lysophosphatidic acid receptor ligands, activators of PPARgamma, and inhibitors of autotaxin. J Med Chem 48 (2005) 4919-4930
41. MOE (2002), Chemical Computing Group, Montreal
42. Halgren T.A. Merck molecular force field. I. Basis, form, scope, parameterization, and performance of MMFF94*. J Comp Chem 17 (1996) 490-519
43. Morris G.M., Goodsell D.S., Halliday R.S., Huey R., Hart W.E., Belew R.K., and Olson A.J. Automated docking using a Lamarckian genetic algorithm and an empirical binding free energy function. J Comput Chem 19 (1998) 1639-1662
44. Ballesteros J.A., and Weinstein H. Chapter 19. In: Conn P.M., and Sealfon S.C. (Eds). Methods in neurosciences (1995), Academic, San Diego 366-428
45. Kates M. Techniques of lipidology (1988), Elsevier, Amsterdam
46. Yue J., Yokoyama K., Balazs L., Baker D.L., Smalley D., Pilquil C., Brindley D.N., and Tigyi G. Mice with transgenic overexpression of lipid phosphate phosphatase-1 display multiple organotypic deficits without alteration in circulating lysophosphatidate level. Cell Signal 16 (2004) 385-399
47. Fischer D.J., Nusser N., Virag T., Yokoyama K., Wang D., Baker D.L., Bautista D., Parrill A.L., and Tigyi G. Short-chain phosphatidates are subtype-selective antagonists of lysophosphatidic acid receptors. Mol Pharmacol 60 (2001) 776-784
48. Balazs L., Okolicany J., Ferrebee M., Tolley B., and Tigyi G. Topical application of the phospholipid growth factor lysophosphatidic acid promotes wound healing in vivo. Am J Physiol Regul Integr Comp Physiol 280 (2001) R466-R472
49. Steiner T. The hydrogen bond in the solid state. Angew Chem Int Ed 41 (2002) 48-76
50. Ohta H., Sato K., Murata N., Damirin A., Malchinkhuu E., Kon J., Kimura T., Tobo M., Yamazaki Y., Watanabe T., Yagi M., Sato M., Suzuki R., Murooka H., Sakai T., Nishitoba T., Im D.S., Nochi H., Tamoto K., Tomura H., and Okajima F. Ki16425, a subtype-selective antagonist for EDG-family lysophosphatidic acid receptors. Mol Pharmacol 64 (2003) 994-1005
51. Brindley D.N., English D., Pilquil C., Buri K., and Ling Z.C. Lipid phosphate phosphatases regulate signal transduction through glycerolipids and sphingolipids. Biochim Biophys Acta 1582 (2002) 33-44
52. van der Bend R.L., de Widt J., van Corven E.J., Moolenaar W.H., and van Blitterswijk W.J. Metabolic conversion of the biologically active phospholipid, lysophosphatidic acid, in fibroblasts. Biochim Biophys Acta 1125 (1992) 110-112
53. Tokumura A., Tsutsumi T., and Tsukatani H. Transbilayer movement and metabolic fate of ether-linked phosphatidic acid (1-O-Octadecyl-2-acetyl-sn-glycerol 3-phosphate) in guinea pig peritoneal polymorphonuclear leukocytes. J Biol Chem 267 (1992) 7275-7283
54. Lai Y.J., Chen C.S., Lin W.C., and Lin F.T. c-Src-mediated phosphorylation of TRIP6 regulates its function in lysophosphatidic acid-induced cell migration. Mol Cell Biol 25 (2005) 5859-5868
55. Oh Y.S., Jo N.W., Choi J.W., Kim H.S., Seo S.W., Kang K.O., Hwang J.I., Heo K., Kim S.H., Kim Y.H., Kim I.H., Kim J.H., Banno Y., Ryu S.H., and Suh P.G. NHERF2 specifically interacts with LPA2 receptor and defines the specificity and efficiency of receptor-mediated phospholipase C-beta3 activation. Mol Cell Biol 24 (2004) 5069-5079
56. Xu J., Lai Y.J., Lin W.C., and Lin F.T. TRIP6 enhances lysophosphatidic acid-induced cell migration by interacting with the lysophosphatidic acid 2 receptor. J Biol Chem 279 (2004) 10459-10468
57. Yamada T., Ohoka Y., Kogo M., and Inagaki S. Physical and functional interactions of the lysophosphatidic acid receptors with PDZ domain-containing Rho guanine nucleotide exchange factors (RhoGEFs). J Biol Chem 280 (2005) 19358-19363
58. Takizawa N., Smith T.C., Nebl T., Crowley J.L., Palmieri S.J., Lifshitz L.M., Ehrhardt A.G., Hoffman L.M., Beckerle M.C., and Luna E.J. Supervillin modulation of focal adhesions involving TRIP6/ZRP-1. J Cell Biol 174 (2006) 447-458
59. Chu F., Borthakur A., Sun X., Barkinge J., Gudi R., Hawkins S., and Prasad K.V. The Siva-1 putative amphipathic helical region (SAH) is sufficient to bind to BCL-XL and sensitize cells to UV radiation induced apoptosis. Apoptosis 9 (2004) 83-95
60. Gudi R., Barkinge J., Hawkins S., Chu F., Manicassamy S., Sun Z., Duke-Cohan J.S., and Prasad K.V. Siva-1 negatively regulates NF-kappaB activity: effect on T-cell receptor-mediated activation-induced cell death (AICD). Oncogene 25 (2006) 3458-3462
61. Xue L., Chu F., Cheng Y., Sun X., Borthakur A., Ramarao M., Pandey P., Wu M., Schlossman S.F., and Prasad K.V. Siva-1 binds to and inhibits BCL-X(L)-mediated protection against UV radiation-induced apoptosis. Proc Natl Acad Sci U S A 99 (2002) 6925-6930